FI104176B1 - Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi - Google Patents

Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi

Info

Publication number
FI104176B1
FI104176B1 FI930753A FI930753A FI104176B1 FI 104176 B1 FI104176 B1 FI 104176B1 FI 930753 A FI930753 A FI 930753A FI 930753 A FI930753 A FI 930753A FI 104176 B1 FI104176 B1 FI 104176B1
Authority
FI
Finland
Prior art keywords
preparation
forfolipid
nucleosides
derivatives
novel antiviral
Prior art date
Application number
FI930753A
Other languages
English (en)
Swedish (sv)
Other versions
FI930753A (fi
FI930753A0 (fi
FI104176B (fi
Inventor
Harald Zilch
Herbert Leinert
Alfred Mertens
Dieter Herrmann
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25896049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI104176(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI930753A publication Critical patent/FI930753A/fi
Publication of FI930753A0 publication Critical patent/FI930753A0/fi
Application granted granted Critical
Publication of FI104176B1 publication Critical patent/FI104176B1/fi
Publication of FI104176B publication Critical patent/FI104176B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI930753A 1990-08-20 1993-02-19 Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi FI104176B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE4026265 1990-08-20
DE4026265A DE4026265A1 (de) 1990-08-20 1990-08-20 Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
PCT/EP1991/001541 WO1992003462A1 (de) 1990-08-20 1991-08-14 Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
EP9101541 1991-08-14
US66103896 1996-06-10
US08/661,038 US5756711A (en) 1990-08-20 1996-06-10 Phospholipid derivatives of nucleosides and their use as anti-viral medicaments

Publications (4)

Publication Number Publication Date
FI930753A FI930753A (fi) 1993-02-19
FI930753A0 FI930753A0 (fi) 1993-02-19
FI104176B1 true FI104176B1 (fi) 1999-11-30
FI104176B FI104176B (fi) 1999-11-30

Family

ID=25896049

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930753A FI104176B (fi) 1990-08-20 1993-02-19 Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi

Country Status (15)

Country Link
US (1) US5756711A (fi)
EP (1) EP0545966B1 (fi)
CN (1) CN1032258C (fi)
AT (1) ATE114316T1 (fi)
CA (1) CA2090024C (fi)
DE (2) DE4026265A1 (fi)
DK (1) DK0545966T3 (fi)
ES (1) ES2066461T3 (fi)
FI (1) FI104176B (fi)
HK (1) HK35597A (fi)
IE (1) IE64374B1 (fi)
NO (1) NO179710C (fi)
PT (1) PT98720B (fi)
SK (1) SK281826B6 (fi)
WO (1) WO1992003462A1 (fi)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
DE4204032A1 (de) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de) * 1992-02-12 1993-08-19 Boehringer Mannheim Gmbh Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
DE4226279A1 (de) * 1992-08-08 1994-02-10 Boehringer Mannheim Gmbh Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
US6080734A (en) * 1992-08-08 2000-06-27 Roche Diagnostic Gmbh Liponucleotides of seco-nucleosides, their production as well as their use as antiviral pharmaceutical agents
DE69431596T4 (de) * 1993-06-10 2003-10-30 University Of North Carolina At Chapel Hill, Chapel Hill (phospho)lipide zum bekämpfen einer hepatitis b-infektion
KR0125779B1 (ko) * 1993-12-04 1997-12-19 김승호 뉴클레오시드 화합물 및 이의 제조방법
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
DE69535758D1 (de) 1994-08-29 2008-07-03 Univ Wake Forest Lipid-analoge zur behandlung von viralen infektionen
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
DK0791056T3 (da) * 1994-11-12 2005-07-04 Heidelberg Pharma Gmbh Lipidopspaltende enzymkompleks
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
DE19547022A1 (de) * 1995-12-15 1997-06-19 Boehringer Mannheim Gmbh Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
DE19602757A1 (de) 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
JP2004509900A (ja) 2000-09-22 2004-04-02 オーファン メディカル,インコーポレイティド 炭水化物、脂質、またはアミノ酸キャリアを含むγ−ヒドロキシブチレート組成物
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CN100469131C (zh) 2001-08-31 2009-03-11 汤姆森许可公司 实现条件存取系统和传输、接收及处理内容的方法和设备
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
NZ533094A (en) * 2001-11-21 2006-01-27 Heidelberg Pharma Gmbh Phospholipid derivatives of nucleosides as antitumoral medicaments
DE10156910A1 (de) * 2001-11-21 2003-06-05 Heidelberg Pharma Holding Gmbh Phospholipid-Derivate von Nucleosiden als antitumorale Arzneimittel
EP1460082A1 (en) 2003-03-19 2004-09-22 Heidelberg Pharma Holding GmbH Phospholipid esters of clofarabine derivatives
WO2006068760A2 (en) * 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
EP1831235B1 (en) * 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US7829548B2 (en) 2004-12-30 2010-11-09 Medivir Ab Compounds useful in the treatment of HIV
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス,インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス,インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
PT2004654E (pt) * 2006-04-04 2013-08-27 Univ California Derivados de pirazolopirimidina para utilização como antagonistas da quinase
GB0608876D0 (en) * 2006-05-05 2006-06-14 Medivir Ab Combination therapy
US7378401B2 (en) 2006-07-14 2008-05-27 Heidelberg Pharma Gmbh Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases
BRPI0817269A2 (pt) 2007-09-26 2014-10-07 Sinai School Medicine Análogos de azacitidina e usos dos mesmos
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン, エルエルシー 特定の化学的実体、組成物および方法
EP3085377A1 (en) * 2008-01-25 2016-10-26 Chimerix, Inc. Methods of treating viral infections
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) * 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
PT2534150T (pt) 2010-02-12 2017-05-02 Chimerix Inc Métodos para tratar uma infecção viral
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
CA2824197C (en) 2011-01-10 2020-02-25 Michael Martin Processes for preparing isoquinolinones and solid forms of isoquinolinones
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン, エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CA2842190A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ[3,4−d]ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
EP3401320B1 (en) 2013-03-15 2020-05-13 The Regents of the University of California Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2016004340A (es) 2013-10-04 2016-08-08 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
RS63250B1 (sr) 2014-09-15 2022-06-30 Univ California Nukleotidni analozi
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
US10377782B2 (en) 2015-09-15 2019-08-13 The Regents Of The University Of California Nucleotide analogs
CN105288648B (zh) * 2015-10-14 2018-11-06 东南大学 一种亲水性药物的磷脂化合物、其药物组合物及应用
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
DE112020006626A5 (de) 2020-03-30 2022-12-08 Chiracon Gmbh Fosalvudin und Fozivudintidoxil zur Anwendung bei der Behandlung der Krankheit Covid-19 und die Verwendung von deren strukturvereinfachten Derivaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291024A (en) * 1978-04-10 1981-09-22 Turcotte Joseph G Cytotoxic liponucleotide analogs
US4283394A (en) * 1979-08-06 1981-08-11 Research Corporation Cytotoxic nucleoside-corticosteroid phosphodiesters
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
DE3778626D1 (de) * 1986-09-27 1992-06-04 Toyo Jozo Kk Nukleosid-phospholipid-konjugat.
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use

Also Published As

Publication number Publication date
DK0545966T3 (da) 1995-05-08
SK9293A3 (en) 1993-07-07
FI930753A (fi) 1993-02-19
CA2090024A1 (en) 1992-02-21
PT98720B (pt) 1999-02-26
NO179710B (no) 1996-08-26
FI930753A0 (fi) 1993-02-19
ES2066461T3 (es) 1995-03-01
HK35597A (en) 1997-03-27
US5756711A (en) 1998-05-26
PT98720A (pt) 1992-07-31
EP0545966B1 (de) 1994-11-23
AU654670B2 (en) 1994-11-17
WO1992003462A1 (de) 1992-03-05
DE4026265A1 (de) 1992-02-27
DE59103595D1 (de) 1995-01-05
IE912930A1 (en) 1992-02-26
EP0545966A1 (de) 1993-06-16
CA2090024C (en) 2000-05-02
IE64374B1 (en) 1995-07-26
NO179710C (no) 1996-12-04
NO930587L (no) 1993-02-19
SK281826B6 (sk) 2001-08-06
CN1032258C (zh) 1996-07-10
NO930587D0 (no) 1993-02-19
ATE114316T1 (de) 1994-12-15
AU8325191A (en) 1992-03-17
FI104176B (fi) 1999-11-30
CN1059149A (zh) 1992-03-04

Similar Documents

Publication Publication Date Title
FI104176B1 (fi) Menetelmä nukleosidien uusien antiviraalisten forfolipidijohdannaisten valmistamiseksi
NL300247I1 (nl) 2-Halogeen-9-(2-desoxy-2-fluor-bêta-D-arabinofuranosyl)-adeninenucleosiderivaten.
DE69021242D1 (de) Antivirale Verbindungen.
IL98702A (en) 9-purinyl phosphonic acid derivatives their preparation and pharmaceutical compositions containing them
IL101583A (en) Quinoxalines processes for their preparation and pharmaceutical compositions containing them
DE3851179D1 (de) Oxetanocin.
DE3369980D1 (en) Disubstituted proline derivatives, process for their preparation and their use
HUT56092A (en) Process for producing 2-amino-pyrimidine-4-carboxamide derivatives and pharmaceutical compositions containing them
ATE9472T1 (de) Amino-desoxy-1.4; 3.6-dianhydro-hexit-nitrate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
HU9301875D0 (en) 4-imino-quinolines, pharmaceutical preparatives containing them and methods for producing said compounds and preparatives
EP0598910A4 (en) METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVES.
ES2067780T3 (es) 2'-desoxi-2'-metilidenocitidina dihidrato, metodos para su produccion y composiciones.
FI102375B1 (fi) Menetelmä deoksinukleosidien valmistamiseksi
HUT56498A (en) Process for producing pharmaceutical compositions having antiviral effect, containing benzylphosphonic acid derivatives
DE69007775D1 (de) 5'-alkylphosphonylnukleoside als antivirale verbindungen.
ES2049186A1 (es) Procedimiento para la preparacion de nuevos derivados de benzofuranil-imidazol.
NO974512L (no) Fremgangsmåte for syntese av nukleosid-analoger
ES2042436T1 (es) Procedimiento mejorado para la preparacion de 2-amino(2,3,5-tri-o-bencil-beta-d-arabinofuranosil)-adenina.
RU94008706A (ru) Производные нуклеозидов, способ их получения и противогерпесная композиция
TH9308A (th) พิริมิดีนคลีโอไซด์ที่ใช้ต้านไวรัส
JPS53144585A (en) Novel uracil derivative and process for its preparation
ES8605819A1 (es) Procedimiento de preparacion de nuevos derivados nucleosidos.
MX9102326A (es) 3-(2-cloro-4-(trifluorometil)fenoxi)-1-acetidina carboxamidas y composicion farmaceutica que las contiene.
DK25184A (da) Terapeutisk virksomme adenosinderivater og fremgangsmaade til fremstilling deraf

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH